2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 975

Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
Abstract Number: 976

Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values
Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Abstract Number: 978

Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 979

Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
Abstract Number: 980

Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort
Abstract Number: 981

New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis
Abstract Number: 982

In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells
Abstract Number: 983

A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Abstract Number: 984

Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus
Abstract Number: 985

IL-6 and TNF-a Cooperate to Modulate Cell Cycle of RA-FLS Via Cyclin Dependent Kinase 6
Abstract Number: 986

Fucosylated Tumor Necrosis Factor α Is Expressed in Rheumatoid Arthritis Synovial Tissues and Is Involved in Monocyte Adhesion
Abstract Number: 987

CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
Abstract Number: 988

Regulatory T Cells with Skewed Responses and Propionate-Producing Gut Bacteria Increased Simultaneously in Patients with Relapsing Polychondritis
Abstract Number: 989

Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].